Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.1.1.42 - isocitrate dehydrogenase (NADP+)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.
Isocitrate dehydrogenase-1 is mutated in inflammatory bowel disease-associated intestinal adenocarcinoma with low-grade tubuloglandular histology but not in sporadic intestinal adenocarcinoma.
Wild-Type Isocitrate Dehydrogenase 1 Over-Expression is Related to Cancer Stem Cells Survival in Lung Adenocarcinoma.
Adenocarcinoma of Lung
Wild-Type Isocitrate Dehydrogenase 1 Over-Expression is Related to Cancer Stem Cells Survival in Lung Adenocarcinoma.
Adenoma
Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa.
alpha-Thalassemia
Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
Arteriovenous Malformations
Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma.
Astrocytoma
A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.
A Simple Panel of IDH1 and P53 in Differential Diagnosis Between Low-Grade Astrocytoma and Reactive Gliosis.
Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma.
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Diagnostic and prognostic markers in gliomas.
Evaluation of the melting temperature of TaqMan probes as a genotyping method for IDH1, IDH2, and H3F3A in pediatric astrocytomas.
Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.
FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas.
Generation and Performance of R132H Mutant IDH1 Rabbit Monoclonal Antibody.
Genetic alterations and signaling pathways in the evolution of gliomas.
Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
IDH1 R132H mutation in a pilocytic astrocytoma: a case report.
IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation.
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Metabolic modulation of epigenetics in gliomas.
Molecular pathogenesis of IDH mutations in gliomas.
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI.
Pathological classification of brain tumors.
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
PCR- and Restriction Endonuclease-Based Detection of IDH1 Mutations.
Spinal Cord Astrocytoma with Isocitrate Dehydrogenase 1 Gene Mutation.
Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients' Diagnosis and Prognosis.
The Role of CASC2 and miR-21 Interplay in Glioma Malignancy and Patient Outcome.
The role of FilGAP, a Rac-specific Rho-GTPase-activating protein, in tumor progression and behavior of astrocytomas.
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Biliary Tract Neoplasms
Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
Brain Neoplasms
5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations.
An R132H Mutation in Isocitrate Dehydrogenase 1 Enhances p21 Expression and Inhibits Phosphorylation of Retinoblastoma Protein in Glioma Cells.
Application of denaturing capillary electrophoresis for the detection of prognostic mutations in isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 genes in brain tumors.
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.
Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report.
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Heterozygous IDH1R132H/WT created by "single base editing" inhibits human astroglial cell growth by downregulating YAP.
High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein.
Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.
IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.
Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis.
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Magnetic resonance spectroscopy for the study of cns malignancies.
Methylation associated genes contribute to the favorable prognosis of gliomas with isocitrate dehydrogenase 1 mutation.
Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
On the Utility of Short Echo Time (TE) Single Voxel 1H-MRS in Non-Invasive Detection of 2-Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel.
Prognostic factors and clinical outcomes in adult primary gliosarcoma patients: a Surveillance, Epidemiology, and End Results (SEER) analysis from 2004 to 2015.
Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients.
Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients.
The effect of race on the prognosis of the glioblastoma patient: a brief review.
Tissue mechanics promote IDH1-dependent HIF1?-tenascin C feedback to regulate glioblastoma aggression.
Breast Neoplasms
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy.
Relationship of glycolytic enzyme activities and response of breast cancer patients to chemotherapy: A preliminary report.
Carcinogenesis
Altered Expression of Oxidative Metabolism Related Genes in Cholangiocarcinomas.
Cancer-associated IDH mutations induce Glut1 expression and glucose metabolic disorders through a PI3K/Akt/mTORC1-Hif1? axis.
Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy.
Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid LeuKemia Patients.
Discovery of ?-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
Intracerebral Distribution of the Oncometabolite d-2-Hydroxyglutarate in Mice Bearing Mutant Isocitrate Dehydrogenase Brain Tumors: Implications for Tumorigenesis.
Isocitrate dehydrogenase 1 is downregulated during early skin tumorigenesis which can be inhibited by overexpression of manganese superoxide dismutase.
Metabolomic comparison between cells over-expressing isocitrate dehydrogenase 1 and 2 mutants and the effects of an inhibitor on the metabolism.
Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H.
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
The emerging role of fumarate as an oncometabolite.
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
Carcinoma
Immunohistochemical Demonstration of Isocitrate Dehydrogenase 1 (IDH1) Mutation in a Small Subset of Prostatic Carcinomas.
Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma.
Proteome of Metastatic Canine Mammary Carcinomas: Similarities to and Differences from Human Breast Cancer (†).
Relationship of glycolytic enzyme activities and response of breast cancer patients to chemotherapy: A preliminary report.
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Carcinoma, Ehrlich Tumor
Changes in enzyme pattern of Ehrlich ascites tumor cells following serial cultivation in media with increased (hypertonic) NaCl content.
Carcinoma, Hepatocellular
Calcium sensitive isocitrate and 2-oxoglutarate dehydrogenase activities in rat liver and AS-30D hepatoma mitochondria.
Carcinoma, Non-Small-Cell Lung
Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
Carcinoma, Renal Cell
Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Carcinoma, Squamous Cell
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Cardiotoxicity
A possible mechanism of adriamycin cardiotoxicity. Inhibition of NADP-linked isocitrate dehydrogenase.
Central Nervous System Neoplasms
Correlation between IDH, ATRX, and TERT promoter mutations in glioma.
Chemical and Drug Induced Liver Injury
[The intensity of free radical oxidation and catalytic properties of the rat liver NADP-isocitrate dehydrogenase in the norm and in toxic hepatitis]
[Thioctic acid action on glutathione-dependent antioxidant system functioning at toxic hepatitis of rats]
Cholangiocarcinoma
A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors.
Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing.
Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma.
Biliary tract cancer.
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options.
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.
Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Mutant IDH inhibits HNF-4? to block hepatocyte differentiation and promote biliary cancer.
Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism.
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Chondroma
Chondroma arising from the spinal dura mater at the thoracic level: A case report with molecular analysis.
Enchondromatosis and Growth Plate Development.
Maffucci Syndrome with Clival Enchondroma in Nasopharynx: A Case Report.
Recurrent 12q13-15 chromosomal aberrations, high frequency of isocitrate dehydrogenase 1 mutations, and absence of high mobility group AT-hook 2 expression in periosteal chondromas.
Chondromatosis
IDH1 mutated acute myeloid leukemia in a child with metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria.
Chondrosarcoma
A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors.
Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing.
An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing.
Association of Clinicopathological Features With Outcome in Chondrosarcomas of the Head and Neck.
Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma.
Chondroma arising from the spinal dura mater at the thoracic level: A case report with molecular analysis.
Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma.
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the Skull Base and tumors involving the facial skeleton and the Layngotracheal tract.
Induction of sarcomas by mutant IDH2.
Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas.
Metabolic consequences of oncogenic IDH mutations.
Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes.
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
NAD Synthesis Pathway Interference is a Viable Therapeutic Strategy for Chondrosarcoma.
Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability.
Novel Multiplex Bead-Based Assay for Detection of IDH1 and IDH2 Mutations in Myeloid Malignancies.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation analysis.
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.
Colorectal Neoplasms
Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.
Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
Coma
[Energy metabolic changes and nerve cell damage in rats exposed to multiple administration of large-dose insulin].
Dehydration
Activity of isocitrate dehydrogenase from three filamentous fungi in relation to osmotic and solute effects.
Sucrose phosphate synthase activity and the co-ordination of carbon partitioning during sucrose and amino acid accumulation in desiccation-tolerant leaf material of the C4 resurrection plant Sporobolus stapfianus during dehydration.
Dermatitis, Phototoxic
Cellular defense against UVB-induced phototoxicity by cytosolic NADP(+)-dependent isocitrate dehydrogenase.
Enchondromatosis
Constitutional abnormalities of IDH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia.
Ovarian cellular fibroma harbouring an isocitrate dehydrogenase 1 (1DH1) mutation in a patient with Ollier disease: evidence for a causal relationship.
The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo.
Ependymoma
Lack of IDH1 mutation in astroblastomas suggests putative origin from ependymoglial cells?
Epilepsy
Correlation Between Tumor Molecular Markers and Perioperative Epilepsy in Patients With Glioma: A Systematic Review and Meta-Analysis.
Esophageal Squamous Cell Carcinoma
Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma.
Fibroma
Ovarian cellular fibroma harbouring an isocitrate dehydrogenase 1 (1DH1) mutation in a patient with Ollier disease: evidence for a causal relationship.
Fibrosarcoma
Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy.
Ganglioglioma
Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas.
Ganglioneuroma
A case of oligodendroglioma with prominent neuronal differentiation.
Glioblastoma
A high-throughput SAMDI-mass spectrometry assay for isocitrate dehydrogenase 1.
A Mistaken Diagnosis of Secondary Glioblastoma as Parasitosis.
A novel isocitrate dehydrogenase 1 G131D mutation in glioblastoma.
A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.
A radiomics-clinical nomogram for preoperative prediction of IDH1 mutation in primary glioblastoma multiforme.
Adult cerebellar glioblastoma cases have different characteristics from supratentorial glioblastoma.
An IDH1-mutated primary gliosarcoma: case report.
Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation.
Angiogenin Upregulation Independently Predicts Unfavorable Overall Survival in Proneural Subtype of Glioblastoma.
Anion-exchange chromatography mass spectrometry provides extensive coverage of primary metabolic pathways revealing altered metabolism in IDH1 mutant cells.
Assessment of the Association between Isocitrate Dehydrogenase 1 Mutation and Mortality Risk of Glioblastoma Patients.
Biochemical, Cellular and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1.
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells.
Clinical Neuropathology Practice News 2-2013: immunohistochemistry pins IDH in glioma - molecular testing procedures under scrutiny.
Clinical prognostic value of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in glioblastoma.
Clinicopathological Analysis of HIF-1alpha and TERT on Survival Outcome in Glioblastoma Patients: A Prospective, Single Institution Study.
Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Correlation of immunohistochemical expression of HIF-1alpha and IDH1 with clinicopathological and therapeutic data of moroccan glioblastoma and survival analysis.
Defective p53 antiangiogenic signaling in glioblastoma.
Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.
Differential and Prognostic Significance of HOXB7 in Gliomas.
Distinct demographic profile and molecular markers of primary CNS tumor in 1873 adolescent and young adult patient population.
EGFR, p53, IDH-1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation.
Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?
Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas.
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
Extracranial Metastasis of IDH-1 Wild Type Glioblastomas.
Friend or foe-IDH1 mutations in glioma 10 years on.
Generation and Performance of R132H Mutant IDH1 Rabbit Monoclonal Antibody.
Genetic alterations and signaling pathways in the evolution of gliomas.
Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation.
Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas.
Glioblastoma in a female neurofibromatosis 1 patient without IDH1, BRAF V600E, and TERT promoter mutations: A case report.
Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations.
Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.
Gliosis versus glioma?: don't grade until you know.
Glutamate is a non-invasive metabolic biomarker of IDH1 mutant glioma response to temozolomide treatment.
Gold Nanoparticle Size and Shape Effects on Cellular Uptake and Intracellular Distribution of siRNA Nanoconstructs.
High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein.
Hominoid-specific enzyme GLUD2 promotes growth of IDH1R132H glioma.
Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
Identification of a long noncoding RNA signature to predict outcomes of glioblastoma.
Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas.
IDH mutations in glioma and acute myeloid leukemia.
IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.
IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice.
IDH1 and IDH2 mutations in gliomas.
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
IDH1 mutation is associated with improved overall survival in patients with glioblastoma: a meta-analysis.
IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location: A case-control study.
IDH1 mutation of gliomas with long-term survival analysis.
IDH1 mutation prediction using MR-based radiomics in glioblastoma: comparison between manual and fully automated deep learning-based approach of tumor segmentation.
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells.
IDH1R¹³²H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
In vivo characterization of physiological and metabolic changes related to isocitrate dehydrogenase 1 mutation expcression by multiparametric MRI and MRS in a rat model with orthotopically grafted human-derived glioblastoma cell lines.
Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry.
Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
Integrative analysis of DNA methylation suggests down-regulation of oncogenic pathways and reduced somatic mutation rates in survival outliers of glioblastoma.
Intramedullary spinal glioblastoma metastasis from anaplastic astrocytoma of cerebellum: A case report and review of the literature.
Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.
Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type.
Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas.
Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Isocitrate dehydrogenase 1 gene variants analysis of glioma patients from Pakistan.
Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience.
Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas: Indication of a significant role of microglia/macrophages in glial tumorigenesis.
Isocitrate dehydrogenase mutations in gliomas.
Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma.
Malignant Transformation of a Rosette-Forming Glioneuronal Tumor with IDH1 Mutation: A Case Report and Literature Review.
Metabolic modulation of epigenetics in gliomas.
Molecular pathogenesis of IDH mutations in gliomas.
MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma.
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Mutant IDH1 Promotes Glioma Formation In Vivo.
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
NADP(+)-dependent IDH1(R132) mutation and its relevance for glioma patient survival.
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
Non-invasive in vivo assessment of IDH1 mutational status in glioma.
Oncogenic MicroRNA-20a is downregulated by the HIF-1?/c-MYC pathway in IDH1 R132H-mutant glioma.
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Phosphorous Magnetic Resonance Spectroscopy and Molecular Markers in IDH1 Wild Type Glioblastoma.
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
Prediction of IDH1 Mutation Status in the Glioblastoma Using the Machine Learning Technique Based on the Quantitative Radiomic Data.
Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy.
Prognostic factors and clinical outcomes in adult primary gliosarcoma patients: a Surveillance, Epidemiology, and End Results (SEER) analysis from 2004 to 2015.
Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
Prognostic value of IDH1 mutations identified with PCR-RFLP assay in glioblastoma patients.
Prognostic Value of MGMT Promoter Methylation and TP53 Mutation in Glioblastomas Depends on IDH1 Mutation.
Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation.
PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.
Radiomic MRI signature reveals three distinct subtypes of glioblastoma with different clinical and molecular characteristics, offering prognostic value beyond IDH1.
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.
Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells.
Sparse Representation-Based Radiomics for the Diagnosis of Brain Tumors.
Spinal Drop Metastasis of Glioblastoma-Two Case Reports, Clinicopathologic Features, Current Modalities of Evaluation, and Treatment with a Review of the Literature.
Structural, Kinetic and Chemical Mechanism of Isocitrate Dehydrogenase-1 from Mycobacterium tuberculosis.
Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
The effect of race on the prognosis of the glioblastoma patient: a brief review.
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.
The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
The role of IDH1 mutated tumour cells in secondary glioblastomas: an evolutionary game theoretical view.
The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.
Transdural Propagation of Glioblastoma Through Foramen Rotundum.
Virtual mutagenesis of isocitrate dehydrogenase 1 involved in glioblastoma multiforme.
Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.
What's New in Grade II and Grade III Gliomas?
[Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma].
Glioma
1P19Q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth.
2-hydroxyglutarate-mediated autophagy of the endoplasmic reticulum leads to an unusual downregulation of phospholipid biosynthesis in mutant IDH1 gliomas.
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.
5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma.
A functional variant on 20q13.33 related to glioma risk alters enhancer activity and modulates expression of multiple genes.
A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
A map of the altered glioma metabolism.
A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres.
A mRMRMSRC feature selection method for radiomics approach.
A novel COLD-PCR/FMCA assay enhances the detection of low-abundance IDH1 mutations in gliomas.
A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.
A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
A Phase Ib Clinical Trial of Metformin and Chloroquine in Patients with IDH1-Mutated Solid Tumors.
A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1.
A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1).
A retrospective analysis of the risk factors affecting recurrence time in patients with recurrent glioblastoma.
A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.
A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up.
Adjunctive perampanel for glioma-associated epilepsy.
Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing.
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.
Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Amide Proton Transfer Imaging in Predicting Isocitrate Dehydrogenase 1 Mutation Status of Grade II/III Gliomas Based on Support Vector Machine.
An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation.
An IDH1-mutated primary gliosarcoma: case report.
An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas.
An R132H Mutation in Isocitrate Dehydrogenase 1 Enhances p21 Expression and Inhibits Phosphorylation of Retinoblastoma Protein in Glioma Cells.
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients.
Analysis of Isocitrate Dehydrogenase 1 Mutation in 97 Patients with Glioma.
Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation.
Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas.
Application of denaturing capillary electrophoresis for the detection of prognostic mutations in isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 genes in brain tumors.
Arterial Spin Labeling for Glioma Grade Discrimination: Correlations with IDH1 Genotype and 1p/19q Status.
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
Association Between Histopathology and Magnetic Resonance Imaging Texture in Grading Gliomas Based on Intraoperative Magnetic Resonance Navigated Stereotactic Biopsy.
Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma.
Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification.
Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.
Brain T1? mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study.
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.
Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma.
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Clinical Neuropathology Practice News 2-2013: immunohistochemistry pins IDH in glioma - molecular testing procedures under scrutiny.
Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
COLD PCR HRM: A highly sensitive detection method for IDH1 mutations.
Combination of the Distance From Tumor Edge to Subventricular Zone and IDH Mutation Predicts Prognosis of Patients With Glioma.
Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
Combined texture analysis of diffusion-weighted imaging with conventional MRI for non-invasive assessment of IDH1 mutation in anaplastic gliomas.
Comparative analysis of the diffusion kurtosis imaging and diffusion tensor imaging in grading gliomas, predicting tumour cell proliferation and IDH-1 gene mutation status.
Comparative study of IDH1 mutations in gliomas by high resolution melting analysis, immunohistochemistry and direct DNA sequencing.
Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
Comprehensive Analysis of Short-, Medium-, and Long-Chain Acyl-Coenzyme A by Online Two-Dimensional Liquid Chromatography/Mass Spectrometry.
Comprehensive Metabolomic Analysis of IDH1R132H Clinical Glioma Samples Reveals Suppression of ?-oxidation Due to Carnitine Deficiency.
Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas.
Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report.
Contrahemispheric Cortex Predicts Survival and Molecular Markers in Patients With Unilateral High-Grade Gliomas.
Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas.
Cystathionine-?-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas.
D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.
D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma.
Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
Detection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies.
Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy.
Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations.
Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma.
Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples.
Diagnostic and prognostic markers in gliomas.
Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants.
Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.
Differential and Prognostic Significance of HOXB7 in Gliomas.
Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
Diffusion kurtosis imaging combined with molecular markers as a comprehensive approach to predict overall survival in patients with gliomas.
Discovery and Optimization of 2H-1?2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer.
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
Dual-Knockout of Mutant Isocitrate Dehydrogenase 1 and 2 Subtypes Towards Glioma Therapy: Structural Mechanistic Insights on the Role of Vorasidenib.
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Enzymes related to energy metabolism in human gliomas.
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation.
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
Exploring the regulatory role of isocitrate dehydrogenase mutant protein on glioma stem cell proliferation.
Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression.
Extent of BOLD Vascular Dysregulation Is Greater in Diffuse Gliomas without Isocitrate Dehydrogenase 1 R132H Mutation.
Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential.
Friend or foe-IDH1 mutations in glioma 10 years on.
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.
Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis.
Gene markers in brain tumors: what the epileptologist should know.
Generation of induced neural stem cells with inducible IDH1R132H for analysis of glioma development and drug testing.
Genotype-targeted local therapy of glioma.
Glioma Cells in the Tumor Periphery Have a Stem Cell Phenotype.
Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1? and ?-catenin signaling: Possible impact on glioma cell metastasis and chemo-resistance.
Glioma grading and IDH1 mutational status: assessment by intravoxel incoherent motion MRI.
Glutamate is a non-invasive metabolic biomarker of IDH1 mutant glioma response to temozolomide treatment.
High DPP4 expression predicts poor prognosis in patients with low-grade glioma.
High S phase kinase-associated protein 2 expression is a potential prognostic biomarker for glioma.
High-frequency oscillations in awake patients undergoing brain tumor-related epilepsy surgery.
High-throughput immunohistochemical profiling of primary brain tumors and non-neoplastic systemic organs with a specific antibody against the mutant isocitrate dehydrogenase 1 R132H protein.
Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.
Identification of a new selective chemical inhibitor of mutant isocitrate dehydrogenase-1.
Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas.
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas.
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
IDH mutations in cancer and progress toward development of targeted therapeutics.
IDH mutations in human glioma.
IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas.
IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.
IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice.
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
IDH1 and IDH2 mutations in different histologic subtypes and WHO grading gliomas in a sample from Northern Brazil.
IDH1 and IDH2 mutations in gliomas.
IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.
IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
IDH1 mutation diminishes aggressive phenotype in glioma stem cells.
IDH1 Mutation in Brain Stem Glioma: Case Report and Review of Literature.
IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas.
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
IDH1 mutation-associated long non-coding RNA expression profile changes in glioma.
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
IDH1 mutations induce organelle defects via dysregulated phospholipids.
IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma.
IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing.
IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
IDH1, lipid metabolism and cancer: Shedding new light on old ideas.
IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
IDH1-R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAR.
IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas.
IDH1/2 mutation detection in gliomas.
IDH1R132H in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis.
IDH1R132H is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment.
IDH1R¹³²H decreases the proliferation of U87 glioma cells through upregulation of microRNA-128a.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.
Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.
Imaging Markers of Isocitrate Dehydrogenase-1 Mutations in Gliomas.
Immunohistochemical Demonstration of Isocitrate Dehydrogenase 1 (IDH1) Mutation in a Small Subset of Prostatic Carcinomas.
In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
In vivo characterization of physiological and metabolic changes related to isocitrate dehydrogenase 1 mutation expcression by multiparametric MRI and MRS in a rat model with orthotopically grafted human-derived glioblastoma cell lines.
Influence of scalp block on oncological outcomes of high-grade glioma in adult patients with and without isocitrate dehydrogenase-1 mutation.
Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1.
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
Interrogation of IDH1 Status in Gliomas by Fourier Transform Infrared Spectroscopy.
Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
Intravoxel incoherent motion magnetic resonance imaging in predicting IDH1 gene mutations in high-grade gliomas.
Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.
Isocitrate Dehydrogenase 1 Analysis Differentiates Gangliogliomas from Infiltrative Gliomas.
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Isocitrate dehydrogenase 1 and 2 mutations in gliomas.
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Isocitrate dehydrogenase 1 gene variants analysis of glioma patients from Pakistan.
Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Isocitrate dehydrogenase 1 mutation is associated with reduced levels of inflammation in glioma patients.
Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma.
Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.
Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
Isocitrate dehydrogenase 1R132H mutation in microglia/macrophages in gliomas: Indication of a significant role of microglia/macrophages in glial tumorigenesis.
Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Isocitrate dehydrogenase mutations in gliomas.
Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
KPNA2 predicts long term survival in patients with anaplastic oligoastrocytomas.
Lack of B and T cell reactivity towards IDH1R132H in blood and tumor tissue from LGG patients.
LncRNA IDH1-AS1 suppresses cell proliferation and tumor growth in glioma.
Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status.
Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.
Management of low-grade glioma: a systematic review and meta-analysis.
Massive dissemination of adult glioblastomas.
Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas.
Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells.
Metabolic consequences of oncogenic IDH mutations.
Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma.
Metabolic Reprogramming in Glioma.
Metabolic reprogramming of pyruvate dehydrogenase is essential for the proliferation of glioma cells expressing mutant IDH1.
Metabolic syndromes and malignant transformation: where the twain shall meet.
Methylation associated genes contribute to the favorable prognosis of gliomas with isocitrate dehydrogenase 1 mutation.
Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.
Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.
Molecular classification of gliomas.
Molecular Immunohistochemical Profile of Angiocentric Glioma.
Molecular markers in low-grade gliomas: predictive or prognostic?
Molecular pathogenesis of IDH mutations in gliomas.
Molecular profile of tumors with oligodendroglial morphology: Clinical relevance.
Morphological and molecular features of astroblastoma, including BRAFV600E mutations, suggest an ontological relationship to other cortical-based gliomas of children and young adults.
Moving toward molecular classification of diffuse gliomas in adults.
MR Imaging-Based Analysis of Glioblastoma Multiforme: Estimation of IDH1 Mutation Status.
MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting.
Multi-institutional noninvasive in vivo characterization of IDH, 1p/19q, and EGFRvIII in glioma using neuro-Cancer Imaging Phenomics Toolkit (neuro-CaPTk).
Multi-Label Nonlinear Matrix Completion With Transductive Multi-Task Feature Selection for Joint MGMT and IDH1 Status Prediction of Patient With High-Grade Gliomas.
Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.
Mutant IDH1 and seizures in patients with glioma.
Mutant IDH1 and thrombosis in gliomas.
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.
Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner.
Mutant IDH1 inhibits PI3K/Akt signaling in human glioma.
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
Mutant IDH1 Promotes Glioma Formation In Vivo.
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance.
Mutant IDH1: An immunotherapeutic target in tumors.
Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.
Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor??B activation in a hypoxia?inducible factor 1?? dependent manner.
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
NAD+ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation.
NADP(+)-dependent IDH1(R132) mutation and its relevance for glioma patient survival.
New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status.
New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
Non-invasive in vivo assessment of IDH1 mutational status in glioma.
Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.
Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability.
Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches.
Novel Multiplex Bead-Based Assay for Detection of IDH1 and IDH2 Mutations in Myeloid Malignancies.
Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas.
Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis.
Oncogenic MicroRNA-20a is downregulated by the HIF-1?/c-MYC pathway in IDH1 R132H-mutant glioma.
Optical analysis of glioma: Fourier-transform infrared spectroscopy reveals the IDH1 mutation status.
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
Papillary tumor of the pineal region: a case involving isocitrate dehydrogenase (IDH) genotyping.
Pathological classification of brain tumors.
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation.
PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas.
Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm.
Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas.
Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.
Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas.
Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Prognostic stratification of gliomatosis cerebri by IDH1(R132H) and INA expression.
Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1.
Qualitative and Quantitative MRI Analysis in IDH1 Genotype Prediction of Lower-Grade Gliomas: A Machine Learning Approach.
Quantitative analysis of neurite orientation dispersion and density imaging in grading gliomas and detecting IDH-1 gene mutation status.
R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes.
R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/?-catenin signaling.
R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1? upregulation in adult glioma.
Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms.
Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing.
Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma.
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.
Re-evaluation of nondiagnostic biopsies of suspected low-grade glioma using isocitrate dehydrogenase 1 mutation immunohistochemistry.
Re-evaluation of the diagnostic performance of 11C-methionine PET/CT according to the 2016 WHO classification of cerebral gliomas.
Relationship between IDH1 mutation and preoperative seizure in low-grade gliomas: A meta-analysis.
RELB: A novel prognostic marker for glioblastoma as identified by population-based analysis.
Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases.
Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Seizures and gliomas - towards a single therapeutic approach.
Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
Sensitive detection of hydroxymethylcytosine levels in normal and neoplastic cells and tissues.
Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
Sparse Representation-Based Radiomics for the Diagnosis of Brain Tumors.
Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.
Synthesis of [1-13 C-5-12 C]-alpha-ketoglutarate enables noninvasive detection of 2-hydroxyglutarate.
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.
TERT and DNMT1 expression predict sensitivity to decitabine in gliomas.
TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis.
Textiloma resembling anaplastic progression of an isocitrate dehydrogenase 1 (IDH1) mutant, low grade glioma.
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
The CpG Island Methylator Phenotype: What's in a Name?
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
The MRI Features and Prognosis of Gliomas Associated With IDH1 Mutation: A Single Center Study in Southwest China.
The neural stem-cell marker CD24 is specifically upregulated in IDH-mutant glioma.
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
The Relationship Between IDH1 Mutation Status and Metabolic Imaging in Nonenhancing Supratentorial Diffuse Gliomas: A 11C-MET PET Study.
The Role of CASC2 and miR-21 Interplay in Glioma Malignancy and Patient Outcome.
The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells.
Tissue mechanics promote IDH1-dependent HIF1?-tenascin C feedback to regulate glioblastoma aggression.
Tissue Thiol Concentration in High-Grade Gliomas: Is There any Association Between IDH1 Mutation Presence and Tumoral Cellular Antioxidant Defense?
To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Unique Interplay Between Molecular miR-181b/d Biomarkers and Health Related Quality of Life Score in the Predictive Glioma Models.
Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets.
Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Usefulness of immunohistochemical expression analysis of metabolic-related molecules to differentiate between intracranial neoplastic and non-neoplastic lesions.
Venous Thromboembolism in Brain Tumors: Risk Factors, Molecular Mechanisms, and Clinical Challenges.
Volume-based histogram analysis of dynamic contrast-enhanced MRI for estimation of gliomas IDH1 mutation status.
Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.
What's New in Grade II and Grade III Gliomas?
[Expression of isocitrate dehydrogenase 1 gene R132H and its diagnostic application in glioma].
[Relationship between IDH1 mutation and clinic pathologic features in human supratentorial WHO grade II gliomas].
Gliosarcoma
An IDH1-mutated primary gliosarcoma: case report.
Prognostic factors and clinical outcomes in adult primary gliosarcoma patients: a Surveillance, Epidemiology, and End Results (SEER) analysis from 2004 to 2015.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
G6pd Deficiency Does Not Affect the Cytosolic Glutathione or Thioredoxin Antioxidant Defense in Mouse Cochlea.
Glucosephosphate Dehydrogenase Deficiency
G6pd Deficiency Does Not Affect the Cytosolic Glutathione or Thioredoxin Antioxidant Defense in Mouse Cochlea.
Hemangioma
Constitutional abnormalities of IDH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia.
Maffucci Syndrome with Clival Enchondroma in Nasopharynx: A Case Report.
Hematologic Neoplasms
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo.
Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered mice.
Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.
Mutant Idh2 cooperates with a NUP98-HOXD13 fusion to induce early immature thymocyte precursor ALL.
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis.
TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
Hyperaldosteronism
Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa.
Hyperglycemia
Upregulation of cytosolic NADP(+)-dependent isocitrate dehydrogenase by hyperglycemia protects renal cells against oxidative stress.
Upregulation of cytosolic NADP+-dependent isocitrate dehydrogenase by hyperglycemia protects renal cells against oxidative stress.
Hypokinesia
[Oxidative enzyme activity of the tricarboxylic acid cycle in rat skeletal muscles in hypokinesia]
Hypothyroidism
Changes of activity and kinetics of certain liver and heart enzymes of hypothyroid and T(3)-treated rats.
Infertility, Male
Identification of miRNAs and their targets by high-throughput sequencing and degradome analysis in cytoplasmic male-sterile line NJCMS1A and its maintainer NJCMS1B of soybean.
Molecular cloning, sequence characterization of a novel pepper gene NADP-ICDH and its effect on cytoplasmic male sterility.
Intellectual Disability
Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
Multicentric Glioma Develops via a Mutant IDH1-Independent Pathway: Immunohistochemical Study of Multicentric Glioma.
isocitrate dehydrogenase (nadp+) deficiency
Mitochondrial NADP+-dependent isocitrate dehydrogenase deficiency increases cisplatin-induced oxidative damage in the kidney tubule cells.
Leukemia
A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3AR882) Demonstrates a Causal Relationship between Its Dominant-Negative Effect and Leukemogenesis.
Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma.
Enzyme activities of NADPH-forming metabolic pathways in normal and leukemic leukocytes.
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Leukemia, Myeloid, Acute
(2R,3S)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia.
A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
A Zebrafish Model for Evaluating the Function of Human Leukemic Gene IDH1 and Its Mutation.
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing.
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.
Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.
Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis.
Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.
Discovery and Optimization of 2H-1?2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer.
Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid Leukemia Cells.
Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Enzyme activities of NADPH-forming metabolic pathways in normal and leukemic leukocytes.
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
FDA Approval Summary: Ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation.
Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish.
IDH mutations in cancer and progress toward development of targeted therapeutics.
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.
IDH1 and IDH2 mutations in pediatric acute leukemia.
IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma.
IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing.
IDH1, lipid metabolism and cancer: Shedding new light on old ideas.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1.
Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.
Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
Inhibitory effects of voriconazole, itraconazole and fluconazole on the pharmacokinetic profiles of ivosidenib in rats by UHPLC-MS/MS.
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review.
Metabolic consequences of oncogenic IDH mutations.
Metabolic syndromes and malignant transformation: where the twain shall meet.
Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability.
Nucleophosmin1 and isocitrate dehydrogenase 1 and 2 as measurable residual disease markers in acute myeloid leukemia.
Oncometabolite d-2-hydroxyglutarate impairs ?-ketoglutarate dehydrogenase and contractile function in rodent heart.
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.
Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Prognostic significance of IDH1 mutations in acute myeloid leukemia: a meta-analysis.
Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance.
Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis.
Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients.
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
The oncometabolite R-2-hydroxyglutarate activates NF-?B-dependent tumor-promoting stromal niche for acute myeloid leukemia cells.
The Synonymous Isocitrate Dehydrogenase 1 315C>T SNP Confers an Adverse Prognosis in Egyptian Adult Patients with NPM1-/CEBPA-Negative Acute Myeloid Leukemia.
Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.
Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.
[Clinical significance of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
[Detection of isocitrate dehydrogenase 1 gene mutation in 205 AML patients and its clinical significance].
Leukemia, T-Cell
Mutant Idh2 cooperates with a NUP98-HOXD13 fusion to induce early immature thymocyte precursor ALL.
Liver Neoplasms
Mutant IDH inhibits HNF-4? to block hepatocyte differentiation and promote biliary cancer.
Lung Neoplasms
Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations.
Lymphoma
Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers.
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Sparse Representation-Based Radiomics for the Diagnosis of Brain Tumors.
Lymphoma, B-Cell
How I treat acute myeloid leukemia in the era of new drugs.
Lymphoma, T-Cell
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
Malaria
NADP-specific isocitrate dehydrogenase from the simian malaria parasite Plasmodium knowlesi: partial purification and characterization.
Melanoma
Advances in Brain Cancer: Creating Monoallelic Single Point Mutation in IDH1 by Single Base Editing.
Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations.
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Metabolic Diseases
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Myelodysplastic Syndromes
Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.
IDH mutations in cancer and progress toward development of targeted therapeutics.
Myelodysplastic Syndrome and Sweet's Syndrome Are Associated with a Mutation in Isocitrate Dehydrogenase 1.
[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].
Myocardial Infarction
[The dose-dependent influence of 3,5-dicarbometoxyphenylbiguanide on activity of the glutathione antioxidant system in heart and blood serum of rats with the experimental myocardial infarction].
Neoplasm Metastasis
Extracranial Metastasis of IDH-1 Wild Type Glioblastomas.
SIRT2-dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases.
Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases.
Neoplasms
A case of multicentric gliomas in both supra- and infratentorial regions with different histology: a case report.
A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
A juvenile case of epilepsy-associated, isocitrate dehydrogenase wild-type/histone 3 wild-type diffuse glioma with a rare BRAF A598T mutation.
A map of the altered glioma metabolism.
A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.
A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.
A PRDX1-p38? heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas.
A strategy for poisoning cancer cell metabolism: Inhibition of oxidative phosphorylation coupled to anaplerotic saturation.
Action at a distance: allostery and the development of drugs to target cancer cell metabolism.
ADHFE1 is a MYC-linked oncogene that induces metabolic reprogramming and cellular de-differentiation in breast cancer.
Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers.
Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors.
Analysis of Mutant Isocitrate Dehydrogenase 1 Immunoexpression, Ki-67 and Programmed Death Ligand 1 in Diffuse Astrocytic Tumours : Study of Single Center in Bandung, Indonesia.
Anaplastic astrocytoma cells not detectable on autopsy following long-term temozolomide treatment: A case report.
Anaplastic astrocytomas with abundant Rosenthal fibers in elderly patients: A diagnostic pitfall of high-grade gliomas.
Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas.
Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays.
Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma.
Awake craniotomies for epileptic gliomas: intraoperative and postoperative seizure control and prognostic factors.
BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.
Biliary cancer: Utility of next-generation sequencing for clinical management.
Biochemical, Cellular and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1.
Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma.
Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
Brain T1? mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study.
Cancer metabolism: Key players in metabolic reprogramming.
Cancer-associated IDH mutations induce Glut1 expression and glucose metabolic disorders through a PI3K/Akt/mTORC1-Hif1? axis.
Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Changes in enzyme pattern of Ehrlich ascites tumor cells following serial cultivation in media with increased (hypertonic) NaCl content.
Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms.
Chondroma arising from the spinal dura mater at the thoracic level: A case report with molecular analysis.
Clinicopathological Analysis of HIF-1alpha and TERT on Survival Outcome in Glioblastoma Patients: A Prospective, Single Institution Study.
Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors.
Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas.
Comparative Analysis of Methods for Detecting Isocitrate Dehydrogenase 1 and 2 Mutations and Their Metabolic Consequence, 2-Hydroxyglutarate, in Different Neoplasms.
Comparative analysis of the diffusion kurtosis imaging and diffusion tensor imaging in grading gliomas, predicting tumour cell proliferation and IDH-1 gene mutation status.
Concurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report.
Congenital glioneuronal tumor with neuropil-like islands.
Congenital oligodendroglioma: clinicopathologic and molecular assessment with review of the literature.
Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress.
Correlation between IDH, ATRX, and TERT promoter mutations in glioma.
Correlation of immunohistochemical expression of HIF-1alpha and IDH1 with clinicopathological and therapeutic data of moroccan glioblastoma and survival analysis.
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Cystathionine-?-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas.
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy.
Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Development of a Rapid and Sensitive IDH1/2 Mutation Detection Method for Glial Tumors and a Comparative Mutation Analysis of 236 Glial Tumor Samples.
Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.
Diffusion kurtosis imaging combined with molecular markers as a comprehensive approach to predict overall survival in patients with gliomas.
Discovery and Optimization of 2H-1?2-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer.
Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.
Discovery of ?-mangostin as a novel competitive inhibitor against mutant isocitrate dehydrogenase-1.
Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Distinct demographic profile and molecular markers of primary CNS tumor in 1873 adolescent and young adult patient population.
Docosahexaenoic Acid Modulates the Enterocyte Caco-2 Cell Expression of MicroRNAs Involved in Lipid Metabolism.
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.
Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Epithelioid glioblastoma presenting as multicentric glioma: A case report and review of the literature.
Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
Exosomal IDH1 increases the resistance of colorectal cancer cells to 5-Fluorouracil.
Exploring the Allosteric Territory of Protein Function.
Extracranial growth of glioblastoma multiforme.
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.
Functional evaluation of isocitrate dehydrogenase 1 and 2 variants of unclear significance in chronic myeloid neoplasms.
Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis.
Generation of induced neural stem cells with inducible IDH1R132H for analysis of glioma development and drug testing.
Genetic alterations and signaling pathways in the evolution of gliomas.
Genetic and Clinical Characterization of HOXB2 in Glioma.
Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors.
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Genetic Factors Affecting Intraoperative 5-aminolevulinic Acid-induced Fluorescence of Diffuse Gliomas.
Genome-wide transcriptional analyses of Chinese patients reveal cell migration is attenuated in IDH1-mutant glioblastomas.
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Gliosarcoma arising from oligodendroglioma (Oligosarcoma): A case report with genetic analyses.
GSH and GABA decreases in IDH1-mutated low-grade gliomas detected by HERMES spectral editing at 3 T in vivo.
Heterozygous IDH1R132H/WT created by "single base editing" inhibits human astroglial cell growth by downregulating YAP.
High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma.
High frequency of H3K27M immunopositivity in adult thalamic glioblastoma.
High-frequency oscillations in awake patients undergoing brain tumor-related epilepsy surgery.
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
Hypoxia Induces Production of L-2-Hydroxyglutarate.
I-8, a novel inhibitor of mutant IDH1, inhibits cancer progression in vitro and in vivo.
Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer.
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.
Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images.
IDH mutations in cancer and progress toward development of targeted therapeutics.
IDH mutations in liver cell plasticity and biliary cancer.
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
IDH1 and IDH2 mutations in gliomas.
IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.
IDH1 mutation of gliomas with long-term survival analysis.
IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation.
IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism.
IDH1 Mutations in Oligodendroglial Tumors: Comparative Analysis of Direct Sequencing, Pyrosequencing, Immunohistochemistry, Nested PCR and PNA-Mediated Clamping PCR.
IDH1 mutations induce organelle defects via dysregulated phospholipids.
IDH1, lipid metabolism and cancer: Shedding new light on old ideas.
IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis.
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.
Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.
Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Immunohistochemical characterisation and histopathology of astrocytic neoplasms at a tertiary Nigerian hospital.
Immunohistochemical Demonstration of Isocitrate Dehydrogenase 1 (IDH1) Mutation in a Small Subset of Prostatic Carcinomas.
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.
Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity.
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
Intracellular cholesterol biosynthesis in enchondroma and chondrosarcoma.
Intraoperative perception and estimates on extent of resection during awake glioma surgery: overcoming the learning curve.
Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer.
Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate.
Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7.
Isocitrate Dehydrogenase 2 Suppresses the Invasion of Hepatocellular Carcinoma Cells via Matrix Metalloproteinase 9.
Isocitrate dehydrogenase variants in cancer - Cellular consequences and therapeutic opportunities.
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Ivosidenib: First Global Approval.
Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.
Lactate dehydrogenase A silencing in IDH mutant gliomas.
Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status.
Long-term tumor control of spinal dissemination of cerebellar glioblastoma multiforme by combined adjuvant bevacizumab antibody therapy: a case report.
Maffucci syndrome and neoplasms: a case report and review of the literature.
Magnetic resonance spectroscopy for the study of cns malignancies.
Malignant glioma: lessons from genomics, mouse models, and stem cells.
Malignant Transformation of a Rosette-Forming Glioneuronal Tumor with IDH1 Mutation: A Case Report and Literature Review.
Metabolic consequences of oncogenic IDH mutations.
Metabolic Reprogramming in Glioma.
Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism.
Molecular Aberrations Associated with Seizure Control in Diffuse Astrocytic and Oligodendroglial Tumors.
Molecular classification of gliomas.
Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.
Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network.
MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors.
MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.
Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes.
Mutant IDH1 and seizures in patients with glioma.
Mutant IDH1 is required for IDH1 mutated tumor cell growth.
Mutant IDH1: An immunotherapeutic target in tumors.
Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.
Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism.
NAD Synthesis Pathway Interference is a Viable Therapeutic Strategy for Chondrosarcoma.
Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.
New Chondrosarcoma Cell Lines with Preserved Stem Cell Properties to Study the Genomic Drift During In Vitro/In Vivo Growth.
New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis.
Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
Novel Multiplex Bead-Based Assay for Detection of IDH1 and IDH2 Mutations in Myeloid Malignancies.
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2.
Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis.
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.
Oncometabolites suppress DNA repair by disrupting local chromatin signalling.
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.
Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis.
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.
Pathologic diversity of glioneuronal tumor with neuropil-like islands: A histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases.
Pathological classification of brain tumors.
PDGFRA Amplification is Common in Pediatric and Adult High-Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma.
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
Phase I trial of intranasal NEO100, highly purified perillyl alcohol, in adult patients with recurrent glioblastoma.
Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
Pilocytic Astrocytoma with Adipocytic Differentiation: A Rare Histological Variation.
Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers.
Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Preoperative neutrophil-lymphocyte ratio correlated with glioma grading and glioblastoma survival.
Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma.
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Promoter methylation of WNT inhibitory factor-1 and expression pattern of WNT/?-catenin pathway in human astrocytoma: pathologic and prognostic correlations.
Quantitative analysis of neurite orientation dispersion and density imaging in grading gliomas and detecting IDH-1 gene mutation status.
R132H Mutation in IDH1 Gene is Associated with Increased Tumor HIF1-Alpha and Serum VEGF Levels in Primary Glioblastoma Multiforme.
Radiomics may increase the prognostic value for survival in glioblastoma patients when combined with conventional clinical and genetic prognostic models.
Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma.
Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics.
Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.
RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer.
Sarcoma-like tumor originating from oligodendroglioma.
Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules.
SIRT2-dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases.
Skeletal spread of an anaplastic astrocytoma (WHO grade III) and preservation of histopathological properties within metastases.
Small interfering RNA-mediated silencing of mitochondrial NADP+-dependent isocitrate dehydrogenase enhances the sensitivity of HeLa cells toward tumor necrosis factor-alpha and anticancer drugs.
Sterol Regulatory Element Binding Protein Regulates the Expression and Metabolic Functions of Wild-Type and Oncogenic IDH1.
Structural basis for multi-specific peptide recognition by the anti-IDH1/2 monoclonal antibody, MsMab-1.
Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
Synthesis of [1-13 C-5-12 C]-alpha-ketoglutarate enables noninvasive detection of 2-hydroxyglutarate.
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The CDKN2A G500 allele is more frequent in GBM patients with no defined telomere maintenance mechanism tumors and is associated with poorer survival.
The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
The effect of race on the prognosis of the glioblastoma patient: a brief review.
The Evaluation of AREG, MMP-2, CHI3L1, GFAP, and OPN Serum Combined Value in Astrocytic Glioma Patients' Diagnosis and Prognosis.
The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.
The Pluripotent Stem-Cell Marker Alkaline Phosphatase is Highly Expressed in Refractory Glioblastoma with DNA Hypomethylation.
The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
The Role of CASC2 and miR-21 Interplay in Glioma Malignancy and Patient Outcome.
The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells.
The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells.
TOF-SIMS analysis of an isocitrate dehydrogenase 1 mutation-associated oncometabolite in cancer cells.
Transcortical insular glioma resection: clinical outcome and predictors.
Tumor location and IDH1 mutation may predict intraoperative seizures during awake craniotomy.
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Unique Interplay Between Molecular miR-181b/d Biomarkers and Health Related Quality of Life Score in the Predictive Glioma Models.
Upregulation of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 Promotes Radioresistance of Glioma by Repressing Semaphorin 5A.
Virtual mutagenesis of isocitrate dehydrogenase 1 involved in glioblastoma multiforme.
Virtual screening of potential anticancer drugs based on microbial products.
Water Networks and Correlated Motions in Mutant Isocitrate Dehydrogenase 1 (IDH1) Are Critical for Allosteric Inhibitor Binding and Activity.
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.
What's New in Grade II and Grade III Gliomas?
Wild-type IDH2 promotes the Warburg effect and tumor growth through HIF1? in lung cancer.
Wild-Type Isocitrate Dehydrogenase 1 Over-Expression is Related to Cancer Stem Cells Survival in Lung Adenocarcinoma.
Withaferin A suppresses tumor promoter 12-O-tetradecanoylphorbol 13-acetate-induced decreases in isocitrate dehydrogenase 1 activity and mitochondrial function in skin epidermal JB6 cells.
[Classification of gliomas. Current progress and perspectives].
[Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma].
[Expression and catalytic properties NADP-isocitrate dehydrogenase from the rat liver under normal conditions and following administration of tumor necrosis factor-alpha or thioctic acid].
[Feature analysis of IDH1 mutation in oligodendroglial tumors].
[Isozymes of NADP-dependent isocitrate dehydrogenase in normal and tumor tissues of various mouse strains and their hybrids]
[Value of Serum Tumor Marker Isocitrate Dehydrogenase 1 in the Diagnosis of Lung Cancer].
Neoplasms, Neuroepithelial
Diffuse leptomeningeal neuroepithelial tumor: 9 pediatric cases with chromosome 1p/19q deletion status and IDH1 (R132H) immunohistochemistry.
Neuroblastoma
Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah's Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia.
Neurocytoma
A case of oligodendroglioma with prominent neuronal differentiation.
Neuroectodermal Tumors, Primitive
Massive dissemination of adult glioblastomas.
Neurofibromatoses
Glioblastoma in a female neurofibromatosis 1 patient without IDH1, BRAF V600E, and TERT promoter mutations: A case report.
Neurofibromatosis 1
Glioblastoma in a female neurofibromatosis 1 patient without IDH1, BRAF V600E, and TERT promoter mutations: A case report.
Oligodendroglioma
A case of oligodendroglioma with prominent neuronal differentiation.
Anaplastic Oligodendroglioma: Advances and Treatment Options.
Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma.
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
Diffuse leptomeningeal neuroepithelial tumor: 9 pediatric cases with chromosome 1p/19q deletion status and IDH1 (R132H) immunohistochemistry.
Findings from positron emission tomography and genetic analyses for cerebellar liponeurocytoma.
Generation and Performance of R132H Mutant IDH1 Rabbit Monoclonal Antibody.
Genetic alterations and signaling pathways in the evolution of gliomas.
Gliosis versus glioma?: don't grade until you know.
IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients.
Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation.
Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
Metabolic modulation of epigenetics in gliomas.
Molecular pathogenesis of IDH mutations in gliomas.
Molecular profile of oligodendrogliomas in young patients.
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
PCR- and Restriction Endonuclease-Based Detection of IDH1 Mutations.
Proteomic analysis of oligodendrogliomas expressing a mutant isocitrate dehydrogenase-1.
Recurrent Glioma With Lineage Conversion From Oligodendroglioma to Astrocytoma in Two Cases.
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Osteosarcoma
The expression and significance of IDH1 and p53 in osteosarcoma.
Up-regulated isocitrate dehydrogenase 1 suppresses proliferation, migration and invasion in osteosarcoma: In vitro and in vivo.
Polycythemia Vera
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
IDH1 and IDH2 mutations in pediatric acute leukemia.
Primary Myelofibrosis
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Reperfusion Injury
Role of cytosolic NADP+-dependent isocitrate dehydrogenase in ischemia-reperfusion injury in mouse kidney.
Retinitis Pigmentosa
Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle.
Retinoblastoma
An R132H Mutation in Isocitrate Dehydrogenase 1 Enhances p21 Expression and Inhibits Phosphorylation of Retinoblastoma Protein in Glioma Cells.
Sarcoma
Glioblastoma in a female neurofibromatosis 1 patient without IDH1, BRAF V600E, and TERT promoter mutations: A case report.
Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations.
Molecular classification of gliomas.
Sheep gene mapping: additional DNA markers included (CASB, CASK, LALBA, IGF-1 and AMH).
[Classification of gliomas. Current progress and perspectives].
Seizures
Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival.
Awake craniotomies for epileptic gliomas: intraoperative and postoperative seizure control and prognostic factors.
High-frequency oscillations in awake patients undergoing brain tumor-related epilepsy surgery.
IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy.
Molecular Aberrations Associated with Seizure Control in Diffuse Astrocytic and Oligodendroglial Tumors.
Mutant IDH1 and seizures in patients with glioma.
New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis.
Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis.
Relationship between IDH1 mutation and preoperative seizure in low-grade gliomas: A meta-analysis.
Tumor location and IDH1 mutation may predict intraoperative seizures during awake craniotomy.
Starvation
Cloning and expression analysis of the cytosolic NADP(+)-dependent isocitrate dehydrogenase from potato. Implications for nitrogen metabolism.
IDH1 Mutation Promotes Tumorigenesis by Inhibiting JNK Activation and Apoptosis Induced by Serum Starvation.
Purification, properties and enhanced expression under nitrogen starvation of the NADP+-isocitrate dehydrogenase from the cyanobacterium Phormidium laminosum.
The NADP+-isocitrate dehydrogenase gene (icd) is nitrogen regulated in cyanobacteria.
Sweet Syndrome
Histiocytoid Sweet syndrome harboring an isocitrate dehydrogenase 1 mutation: A case report and retrospective analysis of 29 cases of histiocytoid Sweet syndrome.
Myelodysplastic Syndrome and Sweet's Syndrome Are Associated with a Mutation in Isocitrate Dehydrogenase 1.
Thrombocythemia, Essential
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.
Thyroid Neoplasms
Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers.
Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Tuberculosis
Determination of Phosphorylation Sites for NADP-specific Isocitrate Dehydrogenase from Mycobacterium tuberculosis.
Structural, Kinetic and Chemical Mechanism of Isocitrate Dehydrogenase-1 from Mycobacterium tuberculosis.
Venous Thromboembolism
Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.
Vitamin E Deficiency
Cellular membranes and membrane-bound enzymes in vitamin E deficiency. A histochemical, cytochemical, biochemical, and morphologic study of the liver of the Pekin duckling.